Business Summary
Maxygen, Inc., a biopharmaceutical company, focuses on developing improved versions of protein drugs. The company utilizes its MolecularBreeding directed evolution technology platform, along with ancillary technologies, and protein modification expertise to pursue the creation of biosuperior proteins. It engages in the discovery, and research and development of multiple protein pharmaceutical programs, including CTLA-4 Ig product candidates that are designed to be CTLA-4 Ig therapeutics for the treatment of an array of autoimmune disorders, including rheumatoid arthritis, and transplant rejection; and MAXY-G34 product candidates for the treatment of chemotherapy-induced neutropenia. The company also focuses on developing biocatalytic process technologies for pharmaceutical, energy, and industrial chemical applications. Maxygen, Inc. was founded in 1996 and is headquartered in Redwood City, California.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM